Rapid Assessment of Cardiovascular Risk Among Users of Smoking Cessation Drugs Within the US Food and Drug Administration's Mini-Sentinel Program

Project Title Rapid Assessment of Cardiovascular Risk Among Users of Smoking Cessation Drugs Within the US Food and Drug Administration's Mini-Sentinel Program
Date
Monday, May 13, 2013
Location
Description

This article describes a Mini-Sentinel modular program-based one-time rapid assessment of the risk of a composite cardiovascular outcome associated with new use of smoking cessation drugs, including varenicline and bupropion. Modular programs are adaptable standardized programs.

Medical Product
bupropion
smoking cessation drug
varenicline tartrate
Health Outcome
acute coronary occlusion without myocardial infarction
acute myocardial infarction (AMI)
cardiovascular outcome
intermediate coronary syndrome
unstable angina
Population / Cohort
All individuals 18 years of age or older
Time Period
2006-2011
Corresponding Author

S. Toh, Department of Population Medicine, Harvard Pilgrim Health Care Institute and Harvard Medical School, 401 Park Drive, Suite 401 East, Boston, MA 02215, USA. E-mail: darren_toh@harvardpilgrim.org

Authors

Sengwee Toh ScD; Meghan A. Baker MD, ScD; Jeffrey S. Brown PhD; Cynthia Kornegay PhD; Richard Platt MD, MS

Data Sources
Mini-Sentinel Distributed Database (MSDD)
Related Assessments